YWYuqi Wen

Yuqi Wen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yuqi Wen has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    MOCSS: Multi-omics data clustering and cancer subtyping via shared and specific representation learning

    by Yuxin Chen, Yuqi Wen, Chenyang Xie, Xinjian Chen, Song He, Xiaochen Bo, Zhongnan Zhang


  • Open Access

    LncRNA-mRNA co-expression analysis revealed 8 core lncRNAs in rheumatoid arthritis of collagen-induced arthritis rats

    by Yuqi Wen, Cailin He, Yang Wang, Siqin Zeng, Bo Yang, Xingui Xiong

    Rheumatoid arthritis (RA) is a chronic inflammatory and autoimmune disease. Current studies suggest that long noncoding RNAs (lncRNAs) may be key regulators in pathogenesis. Analyzed lncRNAs and mRNAs using microarrays to find key differentially expressed lncRNAs in RA. GO and KEGG enrichment analysis together with coding non-coding co-expression (CNC) network was used for comprehensive analysis. Verify that their expression levels are consistent with the chip results by qRT-PCR. There are 268 differentially expressed lncRNAs (DELs) and 286 differentially expressed mRNAs (DEMs). We found 8 core lncRNAs through the CNC network. Eight highly significantly differentially expressed lncRNAs corrected with microarray profiles. The functions and associated pathways of significantly differentially expressed lncRNAs were predicted by GO and KEGG analysis. They may be involved in the pathogenesis of RA. The differential expression profiles of lncRNAs and mRNAs in the collagen-induced arthritis rat model preliminarily predicted functions through comprehensive analysis. However, its exact role and specific mechanism remain to be further studied.


  • Open Access

    COMSUC: A web server for the identification of consensus molecular subtypes of cancer based on multiple methods and multi-omics data

    by Song He, Xinyu Song, Xiaoxi Yang, Jijun Yu, Yuqi Wen, Lianlian Wu, Bowei Yan, Jiannan Feng, Xiaochen Bo

    Extensive amounts of multi-omics data and multiple cancer subtyping methods have been developed rapidly, and generate discrepant clustering results, which poses challenges for cancer molecular subtype research. Thus, the development of methods for the identification of cancer consensus molecular subtypes is essential. The lack of intuitive and easy-to-use analytical tools has posed a barrier. Here, we report on the development of the COnsensus Molecular SUbtype of Cancer (COMSUC) web server. With COMSUC, users can explore consensus molecular subtypes of more than 30 cancers based on eight clustering methods, five types of omics data from public reference datasets or users’ private data, and three consensus clustering methods. The web server provides interactive and modifiable visualization, and publishable output of analysis results. Researchers can also exchange consensus subtype results with collaborators via project IDs. COMSUC is now publicly and freely available with no login requirement at http://comsuc.bioinforai.tech/ (IP address: http://59.110.25.27/). For a video summary of this web server, see S1 Video and S1 File.


  • Open Access

    Drug‐Target Interaction Prediction Based on Adversarial Bayesian Personalized Ranking

    by Yihua Ye, Yuqi Wen, Zhongnan Zhang, Song He, Xiaochen Bo

    The prediction of drug‐target interaction (DTI) is a key step in drug repositioning. In recent years, many studies have tried to use matrix factorization to predict DTI, but they only use known DTIs and ignore the features of drug and target expression profiles, resulting in limited prediction performance. In this study, we propose a new DTI prediction model named AdvB‐DTI. Within this model, the features of drug and target expression profiles are associated with Adversarial Bayesian Personalized Ranking through matrix factorization. Firstly, according to the known drug‐target relationships, a set of ternary partial order relationships is generated. Next, these partial order relationships are used to train the latent factor matrix of drugs and targets using the Adversarial Bayesian Personalized Ranking method, and the matrix factorization is improved by the features of drug and target expression profiles. Finally, the scores of drug‐target pairs are achieved by the inner product of latent factors, and the DTI prediction is performed based on the score ranking. The proposed model effectively takes advantage of the idea of learning to rank to overcome the problem of data sparsity, and perturbation factors are introduced to make the model more robust. Experimental results show that our model could achieve a better DTI prediction performance.


  • Open Access

    PIMD: An Integrative Approach for Drug Repositioning using Multiple Characterization Fusion

    by Song He, Yuqi Wen, Xiaoxi Yang, Zhen Liu, Xinyu Song, Xin Huang, Xiaochen Bo

    The accumulation of various types of drug informatics data and computational approaches for drug repositioning can accelerate pharmaceutical research and development. However, the integration of multi-dimensional drug data for precision repositioning remains a pressing challenge. Here, we propose a systematic framework named PIMD to predict drug therapeutic properties by integrating multi-dimensional data for drug repositioning. In PIMD, drug similarity networks (DSNs) based on chemical, pharmacological, and clinical data are fused into an integrated DSN (iDSN) composed of many clusters. Rather than simple fusion, PIMD offers a systematic way to annotate clusters. Unexpected drugs within clusters and drug pairs with a high iDSN similarity score are therefore identified to predict novel therapeutic uses. PIMD provides new insights into the universality, individuality, and complementarity of different drug properties by evaluating the contribution of each property data. To test the performance of PIMD, we use chemical, pharmacological, and clinical properties to generate an iDSN. Analyses of the contributions of each drug property indicate that this iDSN was driven by all data types and performs better than other DSNs. Within the top 20 recommended drug pairs, 7 drugs have been reported to be repurposed. The source code for PIMD is available at https://github.com/Sepstar/PIMD/.